Captrust Financial Advisors Trims Holdings in Novo Nordisk A/S (NYSE:NVO)

Captrust Financial Advisors lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 12.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 136,586 shares of the company’s stock after selling 18,626 shares during the period. Captrust Financial Advisors’ holdings in Novo Nordisk A/S were worth $11,749,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Center for Financial Planning Inc. boosted its position in shares of Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after buying an additional 123 shares during the period. Strategic Investment Solutions Inc. IL lifted its stake in Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company’s stock worth $27,000 after acquiring an additional 300 shares in the last quarter. Transce3nd LLC purchased a new position in Novo Nordisk A/S during the 4th quarter valued at about $33,000. Kelly Lawrence W & Associates Inc. CA acquired a new position in Novo Nordisk A/S in the 4th quarter valued at about $39,000. Finally, Albion Financial Group UT increased its stake in Novo Nordisk A/S by 121.4% during the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after purchasing an additional 278 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Ratings Changes

NVO has been the subject of a number of research reports. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating for the company. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 25th. Kepler Capital Markets upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. Dbs Bank cut Novo Nordisk A/S to a “sell” rating in a research note on Friday, April 25th. Finally, Guggenheim lowered Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 17th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating, five have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $135.00.

Novo Nordisk A/S Stock Up 1.8 %

Shares of NYSE NVO opened at $67.49 on Thursday. The business has a 50-day moving average of $70.14 and a two-hundred day moving average of $86.94. The company has a market capitalization of $302.88 billion, a price-to-earnings ratio of 20.51, a price-to-earnings-growth ratio of 0.90 and a beta of 0.65. Novo Nordisk A/S has a 1 year low of $57.00 and a 1 year high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.